Showing results (1-10 of 20) with videos related to
Sort By:
Pageof 2
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|October 5, 2022
[Genetic dissection of the molecular mechanism of malignant lymphoma using advanced genomic technology]Sumito Shingaki, Keisuke Kataoka[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|September 9, 2015
[Induction treatment with bortezomib-cyclophosphamide-dexamethasone (CyBorD) for newly diagnosed transplant-eligible patients with multiple myeloma]Nobuhiro Tsukada, Masahiro Ikeda, Sumito Shingaki, et al.International Journal of Hematology|December 26, 2015
High-dose melphalan and autologous stem cell transplantation for systemic light-chain amyloidosis: a single institution retrospective analysis of 40 casesNobuhiro Tsukada, Masahiro Ikeda, Sumito Shingaki, et al.[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|August 11, 2015
[Graft-versus-host disease associated with lenalidomide maintenance after allogeneic transplantation for relapsed/refractory multiple myeloma]Nobuhiro Tsukada, Sumito Shingaki, Masahiro Ikeda, et al.[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|May 23, 2014
Impacts of new agents for multiple myeloma on development of secondary myelodysplastic syndrome and acute myeloid leukemiaAiri Hamano, Sumito Shingaki, Yu Abe, et al.[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|December 16, 2015
[The clinical significance of decrease in CD138 positive cell ratio in multiple myeloma]Junko Inoue, Masahiro Ikeda, Sumito Shingaki, et al.[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|April 7, 2017
Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis during pregnancyMasahiro Ikeda, Rina Oba, Yumiko Yoshiki, et al.International Journal of Hematology|November 6, 2016
Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosisSohsuke Meshitsuka, Sumito Shingaki, Masatoshi Hotta, et al.[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|December 8, 2017
[IgE-κ type multiple myeloma achieving complete response with novel agents]Tomomi Takei, Tadao Ishida, Masahiro Ikeda, et al.Journal of Cancer|May 6, 2020
Use of eribulin as an earlier-line chemotherapy for patients with HER2-negative metastatic breast cancerSumito Shingaki, Takahiro Kogawa, Mototsugu Shimokawa, et al.Pageof 2